By Mill Chart
Last update: Sep 27, 2023
PFIZER INC (NYSE:PFE) has caught the attention of dividend investors as a stock worth considering. NYSE:PFE excels in profitability, solvency, and liquidity, all while providing a decent dividend. Let's delve into the details.
ChartMill employs its own Dividend Rating system for all stocks. This score, on a scale of 0 to 10, is determined by evaluating different dividend factors, such as yield, historical performance, dividend growth, and sustainability. NYSE:PFE has been assigned a 8 for dividend:
ChartMill assigns a proprietary Health Rating to each stock. The score is computed by evaluating various liquidity and solvency ratios and ranges from 0 to 10. NYSE:PFE was assigned a score of 5 for health:
ChartMill utilizes a Profitability Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of profitability ratios and margins, both in absolute terms and in comparison to industry peers. NYSE:PFE has earned a 8 out of 10:
Every day, new Best Dividend stocks can be found on ChartMill in our Best Dividend screener.
Our latest full fundamental report of PFE contains the most current fundamental analsysis.
This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
PFIZER INC
NYSE:PFE (11/30/2023, 12:24:10 PM)
30.385
+0.31 (+1.01%)
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AbbVie, J&J, Eli Lilly, Pfizer are included in this Analyst Blog.
The one thing that experts, along with vaccine makers, can agree on is that low vaccination rates put people at risk of getting severe Covid infections.
Get Anti-inflammatory Drugs Market analysis, key vendors & competitive scenario of the market prepared using market research tools such as Porter’s five forces and SWOT analysis.
Synthetic biology stocks are strongly worth considering for several reasons, particularly these three stocks.
As demand for novel IBD treatments rises, investment in this dynamic sector could be rewarding. Some of the key players in the market are AbbVie (ABBV), J&J (JNJ), Lilly (LLY) and Pfizer (PFE).
CHICAGO - Nov. 29, 2023 - PRLog -- Generis, developer of the CARA Platform for data, content, and business process management, and Risetime, provider of digital content management services for the beauty and life science industries today announced their partnership to offer our customers additional value-add services."We are absolutely thrilled about the incredible opportunities that this partnership brings to the table!" comments Patrick Windsor, Managing Director of Risetime. "By harnessing Risetime's exceptional expertise in FDA regulation and seamlessly integrating it with the cutting-edge CARA Platform, we're setting the stage for an extraordinary level of support to the Cosmetic and Beauty industries, ensuring their complete compliance with MoCRA regulations like never before!"The key focus of this partnership will be the configuration of the CARA Platform for the Cosmetic and Beauty industries and support of the current MoCRA FDA regulations. As a data and content management platform, CARA helps companies in regulated industries such as finance, energy, and manufacturing transform their complex business processes and remain compliant. The unified CARA Life Sciences Platform™ is the pre-configured, out-of-the-box layer with standardised apps for Regulatory, Quality, Safety, and Clinical processes, powered by a single structured data lake that gives users instant access to cross-functional data and enables powerful process optimisation for pharmaceutical companies. This partnership will allow Generis to further expand and fine-tune their offering for the Cosmetics industry."Our partnership with Risetime is a very exciting opportunity." commented James Kelleher, CEO of Generis. "Our CARA Platform provides rich functionality for companies across all regulated industries to remain compliant and keep up with the changing regulations, and with the expertise and guidance provided by the Risetime we can ensure that customers are thriving and improving the way their organisation works."About RisetimeRisetime is a Chicago-based service provider that offers exceptional services to clients across diverse industries with our skilled personnel and robust infrastructure.Our Digital Content Managers use their elevated understanding of healthcare and pharmaceutical industry requirements, to handle assets and metadata correctly in an FDA regulated industry.More at risetime.comAbout GenerisGeneris is a UK-headquartered developer of world-class data, content and business process management for regulated industries globally. 60% of the top 20 life sciences companies rely on Generis' flagship CARA™ Life Sciences Platform, including AbbVie, UCB, Biogen, Reckitt, Bristol Myers Squibb, Bayer, Pfizer, and Merck KGaA. Today Generis serves more than 750,000 users worldwide, across use cases ranging from RIM, Regulatory / R&D and Safety use cases to Clinical, Non-clinical, Quality GxP, CMC, Pharmacovigilance, Medical Information / Medical Affairs applications and more. More at generiscorp.com.
Some of the stocks dumped as funds do tax-loss selling can be attractive buys.
Pfizer and Amazon Web Services are just another example of how artificial intelligence is working in the background in healthcare.
Pfizer Inc is disappointed in its performance versus rival GSK in the RSV vaccine market and is working to pick up market share in 2024, Chief Financial Officer David Denton said on Tuesday. Reuters reported in October that Pfizer's shot was lagging behind the GSK vaccine, which accounted for close to two-thirds of RSV shots given in the U.S. since early September. "If you look at our market share, I don't think we performed as well as we thought we could, or we think we will going forward," Denton told investors at a conference hosted by Evercore ISI analysts.